# ğŸ’¼ Dr Lal PathLabs Ltd â€“ Financial Modeling & DCF Valuation

This project presents a comprehensive **3-statement financial model** and **Discounted Cash Flow (DCF)** based **Valuation** of **Dr Lal PathLabs Ltd**, a leading diagnostics and pathology services provider in India. The model forecasts financial performance from 2026 to 2030 and values the company under Base, Best, and Worst case scenarios.

---

## ğŸ“Š Project Highlights

- âœ… Built complete 3-statement model (Income Statement, Balance Sheet, Cash Flow)
- âœ… Modeled operational drivers such as test pricing, volume, lease costs, and working capital
- âœ… Performed full **DCF valuation** using unlevered free cash flows and terminal value
- âœ… Included **scenario analysis** (Base, Best, Worst) to assess valuation range
- âœ… Developed **sensitivity analysis** across **WACC (8.5%â€“10.5%)** and **terminal multiples (21xâ€“29x)**
---

## ğŸ§® Key Valuation Outputs (Base Case)

| Metric                         | Value (â‚¹ Cr.)        |
|-------------------------------|----------------------|
| Intrinsic Enterprise Value     | â‚¹ 24,570             |
| Intrinsic Equity Value         | â‚¹ 25,563             |
| Intrinsic Share Price          | â‚¹ 3,058              |
| Shares Outstanding (Cr.)       | 8.36                 |
| WACC                           | 9.5%                 |
| Terminal EBITDA Multiple       | 25x                  |
| Terminal Value (2030)          | â‚¹ 33,852             |

ğŸ“ˆ Free cash flows were projected for 2026â€“2030, discounted using WACC, and combined with terminal value to calculate enterprise value.

---

## ğŸ“¦ Files in This Repo

- `DCF_Model.xlsx` â€“ Fully linked and dynamic Excel model
- `Dr_Lal_PathLabs_Ltd.pdf` â€“ Output report and financial schedules
- `valuation_summary.png` â€“ Snapshot of final valuation results

---

## ğŸ“ Key Assumptions

- Revenue growth driven by test volume and pricing scenarios
- Cost inflation modeled for materials and lab test charges
- SG&A fixed as % of revenue
- Straight-line depreciation and amortization
- 25% corporate tax rate

---

## ğŸ”„ Scenario Analysis â€“ Intrinsic Share Price

| Scenario     | Share Price (â‚¹) | **Enterprise Value (â‚¹ Cr.)** |
|--------------|------------------|-------------------------------|
| **Base Case**  | â‚¹ 3,058           | â‚¹ 24,570                      |
| **Best Case**  | â‚¹ 3,305           | â‚¹ 26,637                      |
| **Worst Case** | â‚¹ 2,757           | â‚¹ 22,056                      |

---

## ğŸ“Œ Tools Used

- Microsoft Excel (Advanced formulas, linked schedules)
- Discounted Cash Flow Valuation (DCF)
- Scenario & Sensitivity Analysis
- Financial Statement Analysis

---

## ğŸ§  About the Author

**ğŸ‘¤ Titu Thomas**   
ğŸ“« [LinkedIn](https://linkedin.com/in/titu-thomas-cma) | âœ‰ï¸ tituthomas17@gmail.com



